CDKN2A and neoplasm: HNCs may be evaluated for the presence of HPV-mediated disease via direct methods, e.g., the detection of HPV DNA or mRNA expressed in tumor tissues, or via indirect methods, e.g., the identification of p16Ink4a (p16) expression via immunohistochemistry.